SanBio secures new credit line for AKUUGO® infrastructure

SanBio Company Limited (TSE:4592) announced today the conclusion of a new committed credit line agreement with Mizuho Bank, Ltd. The credit line, dated June 9, 2025, provides JPY 1.0 billion to support the establishment of manufacturing, logistics, and sales systems for AKUUGO® Suspension for Intracranial Implantation. SanBio aims to secure approval for a partial change application for AKUUGO®, which initially obtained conditional and time-limited approval in July 2024. The company currently has an additional committed credit line from Resona Bank, Limited, for JPY 1.0 billion, established in March 2025, also intended for AKUUGO® infrastructure after partial change approval. SanBio anticipates that the new Mizuho Bank agreement will have a minor impact on the company's consolidated earnings for the fiscal year ending January 2026.